Senior Health Plan 2026 Formulary — Part D Coverage Criteria
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines the prescription drugs covered, coverage rules (prior authorization, step therapy, quantity limits), and cost-sharing tiers for Senior Health Plan members of Platinum, Platinum Plus, Silver Plus, and Oklahoma Dual Complete. Applies to plan members and network pharmacies using the 2026 formulary table.
No material clinical or coverage changes in this revision.
Formulary Coverage & Temporary Supply
General formulary coverage
Covered when ALL of the following are met
Standard Part D coverage conditions; see formulary for drug‑specific REQUIREMENTS/LIMITS.
Temporary supply / transition policy
Temporary supply coverage rules
New or continuing members: up to a 30‑day temporary supply. Long‑term care residents: up to a 31‑day emergency supply. Allows time to request a formulary exception or switch therapy.
Temporary supply permits refills to provide up to a 30‑day supply when prescription quantity is written for fewer days.
Formulary coverage entries (table-driven)
Coverage and utilization management as listed in the formulary table for each product
Clinical eligibility criteria are not provided in the table excerpt; use REQUIREMENTS/LIMITS to determine utilization controls and follow plan PA/step procedures.
See table header for symbol definitions and last updated date (03/01/2026).
Formulary coverage by drug entry
Drugs shown are on the Part D formulary with the listed drug tier and any associated requirement/limit codes.
Coverage for the product is subject to the listed requirement/limit codes; obtain prior authorization where indicated and adhere to QL values.
Use the formulary row for the precise tier and REQUIREMENTS/LIMITS when processing coverage requests or claims.
Formulary coverage lines
Coverage and utilization limits are defined per drug line as Tier assignment and REQUIREMENTS/LIMITS entries
Follow the REQUIREMENTS/LIMITS value to determine necessary provider actions (PA submission, documentation, adherence to QL) for coverage.
Documentation supporting PA or dosage (for BvD or NDS entries) should be submitted per plan instructions.
Drugs that are withdrawn from sale by the manufacturer or removed by the FDA for safety or effectiveness reasons may be immediately removed from the formulary and will not be covered. When other formulary changes are made (for example adding a generic or biosimilar, moving a drug to a different tier, or adding utilization controls), the plan will normally provide at least 30 days' notice to affected members before the change is effective, or supply a one-time 30-day refill when a member requests a refill. Members and prescribers may request a formulary exception to continue coverage of a drug affected by such changes; the notice to members will include information on how to request an exception.
The excerpted formulary pages show many product-level entries with DRUG TIER and REQUIREMENTS/LIMITS fields (examples include biologic injectables with NDS PA and QL entries), but there are no categorical or blanket exclusions listed in these chunks. Coverage for each listed product is determined by its line entry (tier plus any requirement codes such as PA, NDS PA, PA_NSO, or QL) rather than by an explicit exclusion statement.
Within the provided extract there are no statements that explicitly exclude classes of drugs or specific products from coverage. The table rows include normal formulary annotations (tier, PA_NSO, PA, QL) that indicate utilization controls; these are not presented in the source as categorical exclusions in this excerpt.
No statements describing drugs as "not medically necessary" (NMN) are present in the supplied excerpt. The document segment focuses on formulary listings, tiers, and requirements/limits rather than explicit NMN determinations.
Formulary Flags, Codes & Quantity Limits (Coding)
| QL=480 ML/30 Days | Qty limit for an oral suspension (example from excerpt) |
| QL=60 EA/30 Days | Qty limit for tablets (example from excerpt) |
| PA_NSO | Prior authorization (non-standard) flag |
| PA_NSO | Prior authorization, non-standard or specialty |
| PA | Prior authorization |
| ST_NSO | Step therapy, non-standard or specialty |
| ST | Step therapy |
| QL | Quantity limit (followed by numeric limits in product lines) |
| INS | Insulin designation/coverage flag |
| PA_BvD | Prior authorization with billing/verification descriptor (as used for FIASP inj) |
| NDS PA | Non-standard dispensing/site prior authorization (appears for mifepristone) |
| citalopram 10mg | citalopram 10mg tab — tier 1 |
| escitalopram 10mg | escitalopram 10mg tab — tier 1 |
| fluoxetine 10mg | fluoxetine 10mg cap — tier 1 |
| paroxetine 20mg | paroxetine 20mg tab — tier 1 |
| sertraline 50mg | sertraline 50mg tab — tier 1 |
| EXXUA 18.2mg/36.3mg/54.5mg/72.6mg ER | EXXUA ER tablets — tier 4, PA_NSO QL=30 EA/30 Days |
| TRINTELLIX 5/10/20mg | TRINTELLIX — tier 3, ST_NSO QL=30 EA/30 Days |
| FETZIMA 20/40/80/120mg ER | FETZIMA — tier 4, PA_NSO QL=30 EA/30 Days |
| desvenlafaxine 25/50/100mg ER | desvenlafaxine succinate ER — tier 2, QL=30 EA/30 Days |
| DRIZALMA 20/30/40/60mg | DRIZALMA DR sprinkle caps — tier 4, PA_NSO QL=60 EA/30 Days |
| OZEMPIC 4MG/3ML PEN INJ | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=3 ML/28 Days |
| OZEMPIC 8MG/3ML PEN INJ | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=3 ML/28 Days |
| RYBELSUS 14MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days |
| RYBELSUS 3MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days |
| RYBELSUS 7MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days |
| TRULICITY 0.75MG/0.5ML AUTO-INJECTOR | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| TRULICITY 1.5MG/0.5ML AUTO-INJECTOR | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| TRULICITY 3MG/0.5ML AUTO-INJECTOR | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| TRULICITY 4.5MG/0.5ML AUTO-INJECTOR | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| FIASP 100UNIT/ML CARTRIDGE | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| FIASP 100UNIT/ML INJ | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS PA_BvD |
| FIASP 100UNIT/ML PEN INJ (3ML) | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMALOG 100UNIT/ML CARTRIDGE | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMALOG 100UNIT/ML KWIKPEN (3ML) | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMALOG 200UNIT/ML KWIKPEN (3ML) | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMALOG JUNIOR 100UNIT/ML PEN INJ (3ML) | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMULIN (70/30) 100UNIT/ML PEN INJ (3ML) | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMULIN N 100UNIT/ML INJ | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS |
| HUMULIN R 500UNIT/ML INJ | DRUG TIER = 3; REQUIREMENTS/LIMITS = INS PA_BvD |
| DAPAGLIFLOZIN 10MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days |
| FARXIGA 10MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days |
| JARDIANCE 10MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days |
| REPATHA 140MG/ML AUTO-INJECTOR | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| REPATHA 140MG/ML SYRINGE | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days |
| alosetron 0.5MG TAB | DRUG TIER = 2; REQUIREMENTS/LIMITS = QL=60 EA/30 Days |
| KLOXXADO 8MG/0.1ML NASAL SPRAY | DRUG TIER = 3; REQUIREMENTS/LIMITS = . |
| naloxone 0.4MG/ML CARTRIDGE | DRUG TIER = 2; REQUIREMENTS/LIMITS = . |
| ondansetron 0.8MG/ML ORAL SOLN | DRUG TIER = 2; REQUIREMENTS/LIMITS = PA_BvD QL=900 ML/30 Days |
| aprepitant 125MG CAP | DRUG TIER = 2; REQUIREMENTS/LIMITS = PA_BvD QL=3 EA/2 Days |
| CRESEMBA 186MG CAP | DRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA |
| fluconazole 100MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| posaconazole 100MG DR TAB | DRUG TIER = 2; REQUIREMENTS/LIMITS = PA QL=96 EA/30 Days |
| voriconazole 200MG TAB | DRUG TIER = 2; REQUIREMENTS/LIMITS = PA QL=120 EA/30 Days |
| ezetimibe 10MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = QL=30 EA/30 Days |
| NEXLETOL 180MG TAB | DRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days |
| atorvastatin 10MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| fenofibrate 134MG CAP | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| gemfibrozil 600MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| rosuvastatin calcium 10MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| simvastatin 10MG TAB | DRUG TIER = 1; REQUIREMENTS/LIMITS = . |
| QL=30 EA/30 Days | Quantity limit: 30 each per 30 days |
| QL=60 EA/30 Days | Quantity limit: 60 each per 30 days |
| QL=120 EA/30 Days | Quantity limit: 120 each per 30 days |
| QL=300 ML/30 Days | Quantity limit: 300 milliliters per 30 days |
| NDS PA | Non-standard/needs prior authorization |
| PA QL=20 EA/10 Days | Prior authorization and quantity limit for DIFICID 200MG TAB / fidaxomicin |
| QL=1800 ML/30 Days | Quantity limit for linezolid 100mg/5ml oral suspension |
| QL=60 EA/30 Days | Quantity limit for linezolid 600mg tab |
| PA_NSO QL=30 EA/30 Days | Prior authorization / special handling and quantity limit for erlotinib formulations |
| NDS PA_NSO QL=60 EA/30 Days | Non-standard dispensing with prior auth and QL for gefitinib / GILOTRIF etc. |
| QL=1 EA/168 Days | TRELSTAR 22.5MG INJ quantity limit |
| QL=1 EA/28 Days | TRELSTAR 3.75MG INJ quantity limit |
| QL=120 EA/30 Days | XTANDI 40MG cap/tab quantity limit |
| QL=60 EA/30 Days | XTANDI 80MG tab quantity limit |
| QL=240 EA/30 Days | ALECENSA 150MG CAP quantity limit |
| QL=30 EA/30 Days | ALUNBRIG 180MG TAB quantity limit |
| QL=90 EA/30 Days | RUBRACA 200MG tab alternative QL |
| QL=28 EA/28 Days | Quantity limit 28 each per 28 days (example format appearing throughout document) |
| QL=120 EA/30 Days | Quantity limit 120 each per 30 days |
| PA_NSO | Prior authorization / Notification status flag used in table |
| NDS PA_NSO | Table notation combining NDS and PA_NSO flag as listed |
| NDS QL=.75 ML/28 Days | INVEGA SUSTENNA 117MG/0.75ML syringe quantity limit |
| NDS QL=1 ML/28 Days | INVEGA SUSTENNA 156MG/ML syringe quantity limit |
| NDS QL=1.50 ML/28 Days | INVEGA SUSTENNA 234MG/1.5ML syringe quantity limit |
| QL=.25 ML/28 Days | INVEGA SUSTENNA 39MG/0.25ML syringe quantity limit |
| NDS QL=.50 ML/28 Days | INVEGA SUSTENNA 78MG/0.5ML syringe quantity limit |
| NDS QL=1 EA/28 Days | ABILIFY MAINTENA quantity limit |
| QL=3.90 ML/56 Days | ARISTADA 1064MG quantity limit |
| NDS QL=1.60 ML/28 Days | ARISTADA 441MG quantity limit |
| NDS QL=2.40 ML/28 Days | ARISTADA 662MG quantity limit |
| QL=2.40 ML/42 Days | ARISTADA 675MG quantity limit |
Prior Authorization, Step Therapy & Documentation Requirements
Prior Authorization Required
Our plan requires prior authorization (PA) for many listed drugs. Providers and members must obtain approval from Community-Care before dispensing or filling prescriptions for drugs marked with PA, PA_NSO, NDS PA, PA_BvD, PA_NSO, or similar flags in the formulary. Failure to obtain required prior authorization may result in the plan denying payment for the drug.
- PA (Prior Authorization) required for many agents; PA_NSO indicates prior authorization required for new starts only.
- NDS PA / NDS flags indicate non-extended day supply and often require PA and limit dispensing to 1-month supplies.
- PA_BvD indicates a Part B vs Part D determination is required; submit clinical setting/use to determine correct benefit.
- PA_NSO and NDS PA_NSO flags are common on specialty and oncology agents; these typically require prior authorization and/or provider notification before coverage.
- Failure to obtain required PA may result in claim denial or non-coverage.
PA and Quantity Limits for Selected Drugs
Selected drug categories and specific products are subject to PA and/or quantity limits (QL). Specialty biologics, oncology agents, GLP-1 agonists/weight-loss agents, PCSK9 inhibitors, certain topical testosterone products, anthelmintics, and many high-cost antivirals/hepatitis therapies explicitly list PA and QL values in the formulary.
- Specialty biologics (e.g., DUPIXENT, FASENRA, NUCALA, XOLAIR, COSENTYX, TREMFYA, SKYRIZI) show PA or NDS PA and defined quantity limits (mL or EA per 28/30/365 days).
- GLP-1 agents (e.g., MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) are marked PA with specific QL (mL or EA per period).
- PCSK9 inhibitors (Repatha) require PA and have volume-based QL (e.g., PA QL=2 ML/28 Days).
- Topical testosterone products require PA with gram-based QL (e.g., PA QL=300 GM/30 Days).
- Anthelmintics: ivermectin 3mg tab requires PA and QL=30 EA/90 Days; albendazole has an annual QL.
PA_NSO / NDS PA_NSO Requirement (New Starts / Non-Standard Dispensing)
Drugs marked with PA_NSO or NDS PA_NSO require additional action on initiation or for non-standard dispensing. Oncology and specialty oral/injectable agents frequently carry NDS PA_NSO indicators; prescribers must obtain PA before the first fill and adhere to any quantity limits shown.
- NDS PA_NSO often appears on anticancer agents, antineoplastics, and some high-cost specialty oral therapies — obtain PA prior to initiation.
- Quantity limits for NDS items may be expressed as EA or mL per 28/30/365 days and must be followed.
- Examples: multiple antineoplastic agents and initiation packs list NDS PA_NSO with explicit QL values.
Insulin PA / Insulin-Specific Requirements
Insulin products have insulin-specific coverage indicators (INS) and some insulin formulations require PA_BvD for Part B vs Part D determination. For insulins marked INS or INS PA_BvD, submit information about intended use/setting as needed and follow insulin program rules (pricing caps may apply).
- Many insulins are labeled INS (covered under insulin program) — check formulary row for INS or INS PA_BvD.
- If PA_BvD is indicated, provide clinical/use setting details to determine Medicare Part B vs Part D coverage before dispensing.
- Examples: FIASP, HUMULIN R 500UNIT/ML, INSULIN LISPRO, LYUMJEV show INS or INS PA_BvD flags.
Specialty Biologic Prior Authorization & Dose/Unit Documentation
Specialty biologics and long-acting injectables require dose/unit documentation and adherence to mL-based quantity limits. Pharmacies and prescribers must submit documentation of dosing schedule, unit volume, and justification when requesting authorization for these agents.
- Formulary rows for biologic injectables specify QL as mL per 28/30/365 days (e.g., DUPIXENT, XOLAIR, TREMFYA, SKYRIZI).
- Dose/unit documentation supports PA requests and ensures dispensing adheres to mL-based limits.
- Long-acting injectables (e.g., depot antipsychotics) may include NDS unit-volume limits — provide administration schedule and unit-dose details with PA.
Documentation & Submission Requirements for PA / Exceptions
When a formulary row displays REQUIREMENTS/LIMITS (PA, QL, ST, NDS, etc.), use those entries as the required documentation checklist when submitting authorizations or prior-notifications. Submit prescriber's supporting statement for formulary exceptions; plan generally decides within 72 hours (or 24 hours for expedited requests).
- Include the formulary REQUIREMENTS/LIMITS code(s) and any quantity (QL) values in the PA submission.
- Prescriber's supporting statement is required for formulary exception determinations; normal response time = 72 hours, expedited = 24 hours when indicated.
- Follow abbreviation guidance at the beginning of the formulary when preparing documentation.
Quantity Limits, Enforcement & Denial Risk
Claims may be denied if prior authorization is not obtained or if dispensed quantities exceed stated QL values. Pharmacies must adhere to QL when filling refills, and prescribers should include QL rationale in PA requests.
- Quantity limit exceedances can trigger denials — examples include linezolid 600mg tab QL=60 EA/30 Days, DIFICID PA QL=20 EA/10 Days, Repatha PA QL=2 ML/28 Days.
- If a prescription exceeds a QL, submit clinical justification with the PA request or seek an exception.
- Pharmacies must follow QL when dispensing partial supplies or mail-order quantities (NDS items limited to 1-month supply).
Step Therapy: Limited/No Explicit Sequences in Excerpt
Step therapy rules are noted where applicable (e.g., ST_NSO for TRINTELLIX). This formulary excerpt contains few explicit step-therapy sequences; where ST or ST_NSO appears, follow the step requirements or request an exception with prescriber's supporting statement.
- TRINTELLIX entries include ST_NSO — step therapy applies for new starts only.
- Most sections in this excerpt do not contain explicit step-by-step algorithms; treat ST flags as indicating a program requirement rather than a detailed sequence.
- Providers may request exceptions if step therapy would cause harm or be ineffective for the member.
Interpretation Guidance: Formulary Flags and Abbreviations
Follow the formulary abbreviation guidance when interpreting flags: PA, QL, ST, NDS, PA_NSO, PA_BvD, ST_NSO, INS, VAC. Use the Requirements/Limits column values as the operational rules for coverage and for preparing PA or exception requests.
- PA_BvD requires submission of use/setting info for Part B vs Part D determination.
- NDS indicates non-extended day supply — limited to 1-month for retail and mail order; check QL values.
- When in doubt, reference the formulary legend at the start of the drug table for symbol definitions.
Step Therapy Indicators & Class-Level Rules
| Coverage label | Summary |
|---|---|
| ST / ST_NSO | |
| Members must try specified preferred drugs before coverage of some non-preferred drugs. ST_NSO (Step Therapy for New Starts Only) applies to drugs newly started by a member; the member must try the required alternative(s) first or obtain an exception prior to coverage. |
| Coverage label | Interpretation |
|---|---|
| Class-level REQUIREMENTS/LIMITS | |
| Some therapeutic classes display 'REQUIREMENTS/LIMITS' at the class header which suggests program‑level rules or step edits may apply (for example ADHD and amphetamine class headers). Specific per‑drug step sequences are not detailed in this excerpt and would be defined elsewhere in the formulary or plan policy. |
| Coverage label | Note |
|---|---|
| Biologics / Specialty injectables | |
| No explicit step therapy steps for listed biologics are shown in these chunks. Biologic lines are annotated with prior authorization and non‑standard dosing/dispensing flags (e.g., NDS PA, NDS PA QL values) indicating PA and quantity limits govern coverage rather than step sequencing in this excerpt. |
| Coverage label | Summary |
|---|---|
| Step therapy absent | |
| No explicit step therapy sequences are listed in the provided chunks; prior authorization (PA), PA_BvD, PA_NSO, and quantity limits (QL) are the primary utilization controls shown. |
| Coverage label | Implication for providers |
|---|---|
| PA_NSO | |
| PA_NSO indicates a prior authorization requirement (often for specialty products) that applies to new starts; while it implies a clinical review or approval is required before coverage, no step therapy sequences are provided in these chunks. |
| Drug | Step therapy flag / Note |
|---|---|
| TRINTELLIX (5mg, 10mg, 20mg) | |
| Marked ST_NSO with QL=30 EA/30 Days — indicates step therapy for new starts only (ST_NSO). Providers should obtain prior approval or document trial of preferred agents for new starts per plan rules. |
| Coverage label | Effect on coverage |
|---|---|
| PA_BvD | |
| PA_BvD appears on several antiemetic/supportive care agents (e.g., ondansetron, aprepitant) indicating a prior authorization/benefit determination is required — implying clinical review prior to approval rather than an explicit step sequence. |
| Drug | Requirement |
|---|---|
| metyrosine 250mg cap | |
| Listed with NDS PA — requires prior authorization before coverage. No step therapy sequence is specified in the excerpt. |
| Coverage label | Comment |
|---|---|
| Antineoplastic agents with NDS PA_NSO | |
| Several high‑tier antineoplastic agents are annotated NDS PA_NSO (non‑standard dispensing / prior authorization/notification) and have quantity limits; these flags indicate special authorization/dispensing requirements prior to coverage rather than explicit step therapy sequences. |
| Coverage label | Interpretation |
|---|---|
| Requirement codes (PA / NDS / NSO) | |
| Products flagged with PA, NDS, NSO, PA_NSO, or similar codes may imply plan‑level utilization management or step requirements, but explicit step/failure sequences are not present in these chunks and would be defined in the plan’s PA/step policy documentation. |
| Example | Notes |
|---|---|
| aripiprazole ODT (example lines) | |
| Flagged PA_NSO with QL=60 EA/30 Days in the formulary — demonstrates a prior authorization/quantity limit requirement on an oral product. No step sequencing logic is provided in the excerpt. |
Quantity Limits (QL) per Drug Example
Site of Care & Dispensing Notes
Table Abbreviations & Legend
Policy Background & Scope
This document is the Senior Health Plan Medicare Part D formulary for 2026. It lists covered prescription drugs organized by therapeutic class and by individual drug strength/formulation, shows the drug tier assignment for each line, and records plan-level utilization controls such as Prior Authorization (PA), specialty prior authorization markers (e.g., NDS PA, PA_NSO), step therapy flags (e.g., ST_NSO), and Quantity Limits (QL) expressed as an amount per time period (for example, QL=30 EA/30 Days or QL=3 ML/28 Days). The formulary also explains that biosimilars and interchangeable products may be managed per plan and state rules, and directs prescribers and pharmacies to follow the REQUIREMENTS/LIMITS entries when submitting prior authorization requests or claims.
Document Updates & Review Dates
Policy last reviewed on 2026-02-18 as recorded in the document metadata.
Formulary pages show a 'Last Updated Date: 03/01/2026' timestamp on multiple table pages indicating content updates posted on 03/01/2026.
Formulary table sections include 'Last Updated Date: 03/01/2026' (repeated on several pages), reflecting a table-level update posted 03/01/2026.
Document footer and multiple content sections display 'Last Updated Date: 03/01/2026', indicating the document was updated on 03/01/2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.